Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Beyond statin therapy: why we need new thinking.

Gerd Assmann1

  • 1Institute of Clinical Chemistry and Laboratory Medicine, Westphalian Wilhelms-University, Muenster, Germany. assmann@uni-muenster.de

Current Medical Research and Opinion
|September 6, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiovascular Risk Factors Associated With Venous Thromboembolism.

JAMA cardiology·2019
Same author

Equalization of four cardiovascular risk algorithms after systematic recalibration: individual-participant meta-analysis of 86 prospective studies.

European heart journal·2018
Same author

Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies.

Lancet (London, England)·2018
Same author

Use of Repeated Blood Pressure and Cholesterol Measurements to Improve Cardiovascular Disease Risk Prediction: An Individual-Participant-Data Meta-Analysis.

American journal of epidemiology·2017
Same author

Association of Cardiometabolic Multimorbidity With Mortality.

JAMA·2015
Same author

Treat-to-target versus dose-adapted statin treatment of cholesterol to reduce cardiovascular risk.

European journal of preventive cardiology·2015
Same journal

Seasonal variations and prognosis of patients with sepsis, septic shock, and cardiogenic shock.

Current medical research and opinion·2026
Same journal

Therapeutic use of cardioselective beta-blockers for patients with chronic obstructive pulmonary disease: a review of current clinical evidence.

Current medical research and opinion·2026
Same journal

Treatment patterns among pediatric and adult patients with ulcerative colitis in the United States: a retrospective cohort study.

Current medical research and opinion·2026
Same journal

Multidrug-resistant <i>Pseudomonas aeruginosa</i> in Jordan: epidemiology, trends, determinants, and clinical outcomes.

Current medical research and opinion·2026
Same journal

RSV disease and vaccination knowledge, attitudes, and practices among US adults: a 2024-2025 RSV season survey.

Current medical research and opinion·2026
Same journal

Clinical and healthcare resource utilization outcomes following revision knee arthroplasty with and without a gradually reducing radius revision knee system.

Current medical research and opinion·2026
See all related articles

Current cardiovascular guidelines focus on low-density lipoprotein cholesterol (LDL-C) and statins. Emerging evidence highlights high-density lipoprotein cholesterol (HDL-C) and lipoprotein (a) [Lp(a)] as crucial for comprehensive cardiovascular risk assessment and management.

Area of Science:

  • Cardiology
  • Lipidology
  • Preventive Medicine

Background:

  • Current cardiovascular event prevention guidelines primarily target low-density lipoprotein cholesterol (LDL-C), often via statin therapy, achieving about 30% risk reduction.
  • However, residual cardiovascular risk remains, prompting investigation into other lipid parameters.
  • Epidemiological studies, like PROCAM, identify low high-density lipoprotein cholesterol (HDL-C) and high lipoprotein (a) [Lp(a)] as significant risk factors.

Purpose of the Study:

  • To review the role of HDL-C and Lp(a) in cardiovascular risk beyond LDL-C targets.
  • To discuss updated guidelines incorporating emerging cardiovascular risk factors.
  • To highlight HDL-C raising as a therapeutic strategy for specific patient groups.

Main Methods:

Related Experiment Videos

  • Analysis of epidemiological data, including the Prospective Cardiovascular Münster (PROCAM) study.
  • Review of current international guidelines for cardiovascular disease prevention.
  • Examination of the atheroprotective and atherothrombotic roles of HDL-C and Lp(a).

    • Main Results:

    • HDL-C plays multiple atheroprotective roles beyond reverse cholesterol transport.
    • Lp(a) is implicated in increasing atherothrombotic responses.
    • New guidelines consider both classical and emerging risk factors, including HDL-C and Lp(a), for global cardiovascular risk assessment.

    Conclusions:

    • Elevated Lp(a) and low HDL-C are important modulators of global cardiovascular risk.
    • Guidelines now advocate for raising HDL-C in at-risk patients with specific triglyceride and HDL-C levels.
    • While Lp(a) is not yet a direct intervention target, its inclusion in risk assessment is crucial.